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Introduction
Lung cancer causes about 1.4 million deaths per year world-
wide (1). Non-small cell lung cancer (NSCLC) accounts 
for approximately 85% of lung cancer. Only a fraction of 
NSCLC patients are diagnosed with localized, early-stage 
disease, when curative-intent surgical resection is possible 
(2,3). After surgery, the status of regional lymph node (LN) 
involvement is the most important prognostic factor (4). 
Pathologic nodal involvement (pN1-3) connotes a poor 
prognosis, but also predicts the likelihood of benefit from 
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postoperative adjuvant therapy. Multiple investigators have 
demonstrated the heterogeneity in survival of patients with 
pN0 resections, suggesting the possibility that a significant 
proportion of these patients are understated, probably 
because LN metastasis is missed (5-8). However, the 
survival of patients with pathologic N1 is also heterogenous, 
ranging from a 5-year survival of 54% to 34% in the 
International Association for the Study of Lung Cancer 
(IASLC) Lung Cancer Staging Project database (4). The 
reported risk of recurrence for patients with pathologic 
Stage IIA-IIB disease ranges from 7% to 55% (9).
These results suggest a need to identify patterns of 
LN involvement that more accurately predict survival, 
particularly of patients with N1 disease (10,11). Because 
the thoroughness of nodal examination interacts with 
the likelihood of detecting nodal metastasis, the number 
of positive LNs may depend on by the number of LNs 
examined from the resection specimen. Therefore, the 
prognostic accuracy of the actual number of positive LNs is 
potentially restricted (12). The lymph node ratio (LNR)—
the number of positive LNs divided by the number of 
LNs examined- has been suggested to be a more accurate 
prognostic indicator than the number of LNs with 
metastasis in different types of cancer including thyroid, 
gastric, colorectal, and cancer (13-19). 
The prognostic value of the LNR in N1 NSCLC 
remains controversial. We conducted a meta-analysis 
of published reports in order to evaluate the LNR as 
a predictor of survival and recurrence in patients with 
pathological N1 NSCLC. 
Methods
Search strategy
We comprehensively search PubMed and ISI Web of 
Science using an upper date limit of March 17, 2016, and 
no lower date limit. Search terms included: “lymph node 
ratio”, “LNR” “non-small cell lung cancer”, “NSCLC”, “N1 
node”. References cited in the identified publications were 
also used to complete the search.
Inclusion criteria
Two of the authors (Qian Li, Ping Zhan) independently 
determined the eligibility of the studies retrieved from 
the databases and bibliographies (Figure 1). Studies 
eligible for inclusion in this meta-analysis met the 
following criteria: include early stage NSCLC patients 
who underwent surgical resection; include the patients 
harboring pathological N1 disease; provide information 
on survival (studies investigating response rates only were 
excluded); have a follow-up time not less than two years; 
and for multiple publications reporting on the same patient 
population, only the most recent, or the most complete, 
report was included. Discordance among reviewers was 
resolved by mutual agreement after further discussion.
Exclusion criteria
Publications were excluded if they met any of the following 
criteria: (I) case series, case reports, reviews and conference 
Figure 1 Flow chart representing the process of literature search and study selection.
Literature search
Databases: PubMed, ISI Web of science
Manually search: refernce section of selected 
studies and relevant reviews
402 citations excluded after screening
1 citations coming from same population 
2 articles without related data
13 articles about N2 or N1 plus N2
5 articles finally included
423 citations retrieved
21 articles assessed for eligibility
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reports; (II) duplicate publications; (III) studies based on 
overlapping cohorts from the same institution.
Data extraction and quality assessment
The final articles included were assessed independently 
by two reviewers (Qian Li and Ping Zhan) using the 
“Newcastle-Ottawa Scale for Assessing the Quality of Non-
Random Studies in Meta-analyses” (20). Given the variability 
in the quality of cohort studies found in our initial literature 
search, we considered studies to be of high quality if they 
achieved a score of six or more on the Newcastle-Ottawa 
Scale. Data retrieved from the reports included first author, 
year of publication, country, lung cancer stage, number of 
patients, time, and survival data (Table 1).
Definition of outcomes
The primary outcome was overall survival (OS), measured 
from the date of surgery to the date of death or date of last 
follow-up; the secondary outcome was disease-free survival 
(DFS), measured from the date of surgery to the date of 
disease progression or date of last follow-up.
Statistical methods
The hazard ratios (HRs) and their 95% confidence 
intervals (CIs) were combined to give the pooled effective 
value. Heterogeneity of the individual HRs was calculated 
with Chi-squared tests according to Peto’s method (21). 
Heterogeneity test with I2 statistic was performed. All 
the studies included were categorized by OS and DFS. 
Individual meta-analysis was conducted in each subgroup. 
If HRs were found to have acceptable homogeneity, a 
fixed effect model was used for secondary analysis; if not, a 
random effect model was used. 
In this meta-analysis, Der Simonian Laird random 
effects analysis was used to estimate the effect of N1 LNR 
on survival (22). HR >1 indicates better survival of low N1 
LNR, conversely, HR <1 implies worse survival for the 
group with high N1 LNR. The impact of N1 LNR on 
survival was considered to be statistically significant if the 
95% CI did not overlap with 1. Horizontal lines represent 
95% CIs. The HR point estimate was reflected in each 
box and the box area is proportional to the weight of the 
study. The diamond (and broken line) represents the overall 
summary estimate, with CI represented by its width. The 
unbroken vertical line is set at the null value (HR =1.0).
Existence of publication bias was evaluated by the 
methods of Begg et al. (23). Moreover, a contour-enhanced 
funnel plot was performed to aid in interpreting the funnel 
plot (24). Publication bias can lead to the asymmetry that 
studies appear to be missing in areas of low statistical 
significance, while it is less likely to cause the funnel 
asymmetry under the circumstance of studies missing in 
areas of high statistical significance. Intercept significance 
was determined by the t-test suggested by Egger (25). 
Statistical analysis was conducted using STATA version 11.0 
(Stata Corporation, College Station, TX, USA).
Results
Study selection and characteristics 
Five studies published between 2010 and 2014 were eligible 
for this systematic review with meta-analysis (26-30). All 
reported the prognostic value of LNR in patients with 
pathologic N1 NSCLC. The total number of patients 
included was 6,130, ranging from 75 to 4,004 patients 
per study. The major characteristics of the five eligible 
publications are reported in Table 1.
Table 1 Clinical and methodological characteristics of included studies
First author, year Country Stage N pts Time (year)
HR (95% CI)
OS DFS
Wisnivesky, 2011 US T1a-T3N1 1,682 1992–2005 1.56 (1.10–2.21) 1.55 (1.03–2.33)
Jonnalagadda, 2011 US N1 positive 4,004 1988–2007 1.51 (1.04–2.19) 1.58 (1.04–2.40)
Wu, 2014 Taiwan/China IIA 75 2005–2011 2.81 (1.08–7.31) 2.36 (1.32–4.22)
Li, 2013 China II 206 1999–2009 1.57 (1.01–2.45) –
Liu, 2013 Taiwan/China II 163 1992–2010 1.40 (0.85–2.35) –
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; N pts, number of patients; OS, overall survival; US, the United States 
of America.
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Meta-analysis
The results of the meta-analysis are reported in Figures 
2, 3 and 4. Overall, the pooled HR for all eligible studies 
evaluating the OS of high N1 LNR in resected early-stage 
NSCLC was 1.53 (95% CI: 1.22–1.85) using the fixed effects 
model (Figure 2). The heterogeneity between the reports 
was not significant (I2=0.0%, P=0.940). The HR indicates 
that in patients with pathologic N1 NSCLC, those with 
higher LNR had poor survival compared to those with lower 
LNR. Higher LNR was also associated with shorter DFS, 
as the pooled HR for DFS was 1.64 (95% CI: 1.19–2.09) 
(only 3 of the 5 studies had data available for DFS) (Figure 3). 
Again, the heterogeneity between the reports was not 
significant (I2=0.0%, P=0.591). 
Figure 2 Meta-analysis of the association between N1 LNR and OS in patients with pathological N1 non-small cell lung cancer (NSCLC). 
Results are presented as the individual and summarized hazard ratios (HRs) with 95% confidence interval (CI). Each box represents the 
OR point estimate, and its area is proportional to the weight of the study. The diamond (and broken line) represents the overall summary 
estimate, with CI represented by its width. The unbroken vertical line is set at the null value (OR =1.0). LNR, lymph node ratio; OS, overall 
survival; OR, odds ratios.
Figure 3 Meta-analysis of the association between N1 LNR and DFS in patients with pathological N1 NSCLC. Results are presented as the 
individual and summarized HR with 95% CI. Each box represents the OR point estimate, and its area is proportional to the weight of the 
study. The diamond (and broken line) represents the overall summary estimate, with CI represented by its width. The unbroken vertical line 
is set at the null value (OR =1.0). LNR, lymph node ratio; DFS, disease-free survival; NSCLC, non-small cell lung cancer; CI, confidence 
interval; OR, odds ratios.
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Begg’s funnel plot was performed to assess publication 
bias in the included literature. All five eligible studies 
investigating NSCLC patients yielded a Begg’s test score of 
P=0.806. Furthermore, according to the contour-enhanced 
funnel plot (Figure 4), no evidence of publication bias was 
found in all five studies. 
Discussion
The status of LNs is a powerful determinant of survival in 
NSCLC and an essential component of the tumor, node, 
metastasis (TNM) classification for lung cancer (3,4). The 
TNM NSCLC staging system currently uses only the 
anatomic location of LNs to define N status. The LNR has 
been shown to be an important prognostic factor in several 
malignancies (13-19) and may overcome the limitation in 
the number of LNs sampled. Consistent with this notion 
Bria et al. showed an association between the LNR and lung 
cancer outcomes (12).
In this meta-analysis, we have combined five published 
studies including 6,130 NSCLC patients with pathologic 
N1 NSCLC to evaluate the prognostic value of the LNR. 
Our results show high N1 LNR is significantly associated 
with worse OS [HR 1.53 (95% CI: 1.22–1.85)] and DFS [HR 
1.64 (95% CI: 1.19–2.09)]. Therefore, the LNR should be 
considered a predictor of survival and recurrence in patients 
with pathologic N1 NSCLC. The higher LNR, the worse 
the prognosis.
Surgical resection is the key curative treatment modality 
for patients with N1 NSCLC (31). However, patients 
with pathologic N1 disease have heterogeneous outcomes 
(4,9,32). For example, in the IASLC’s Lung Cancer Staging 
Project database, intercontinental pathologic N1 5-year 
survival rates ranged from 54% in Asia to 34% in Europe (4). 
Some have proposed that this survival heterogeneity 
is partly driven by heterogeneity in staging accuracy 
caused by heterogeneity in the thoroughness of hilar and 
intrapulmonary LN retrieval (33-35). The value of the 
LNR may be in partially adjusting for this heterogeneity in 
thoroughness of nodal evaluation. 
Current guidelines on lung cancer surgery do not 
specify the number of LNs that should be sampled for 
adequate staging. Several large population-based studies 
have suggested that more than ten LNs should be examined 
in the resection specimens of patients categorized as 
pathologic node-negative (5-8). There has been less 
emphasis on the need for thorough N1 nodal examination 
in patients with pN1 disease. However, the burden of 
metastatic disease, reflected by the number or proportion 
of LNs with metastasis, may have great prognostic 
significance. The total number of N1 nodes detected with 
metastasis is, theoretically, limited by the total number of 
LNs examined. Our results support using the LNR as an 
independent means of risk-stratifying patients with pN1, 
and potentially identifying patients who might benefit from 
more intense postoperative adjuvant therapy, might need 
closer surveillance, or might be targeted for enrollment into 
clinical trials of novel adjuvant therapies. 
Potential limitations of our study include the limitation 
to articles published in the English language, the possibility 
of a publication bias, since we could not include studies that 
may not have been published because of negative results, 
and the small number of eligible studies in this meta-
analysis. Despite these limitations, our study shows that 
a high LNR connotes a poor prognosis in patients with 
resected N1 NSCLC. The LNR should be considered in 
determining post-operative management of patients with 
pN1, because it provides a more accurate assessment of 
prognosis.
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